AstraZeneca PLC
AZN: XLON (GBR)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
GBX 72,298.00 | Pyc | Ccjfjjfb |
AstraZeneca Earnings: Solid Results Led by Cancer Drugs as Pipeline Makes Strides
AstraZeneca reported third-quarter results largely in line with our expectations, and we are holding firm to our fair value estimate. We continue to view the stock as undervalued with the market is likely underappreciating the company's pipeline and overall growth potential.